Exelixis Inc. expanded its courtroom offensive protecting its cancer drug Cabometyx, alleging in a new lawsuit that Teva Pharmaceutical Industries Ltd.’s proposed copy infringes another patent for the blockbuster pharmaceutical, even as Exelixis faces a different generic-drug maker’s accusation that it improperly acquired three crucial Cabometyx patents in pursuit of a “thicket.”
Exelixis seeks an order blocking the effective date of any US Food and Drug Administration approval of Teva’s copy until the patent expires in February 2032, according to a complaint filed Sept. 2 in the US District Court for the District of Delaware.
That’s more than eight years ...
